The influence of cigarette smoking on viral infections: Translating bench science to impact COPD pathogenesis and acute exacerbations of COPD clinically

Chest

Volumn 143, Issue 1, 2013, Pages 196-206

  Bauer, Carla M T ^a   Morissette, Mathieu C ^b   Stämpfli, Martin R ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON RECEPTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 8; PURINERGIC P2X7 RECEPTOR; TOLL LIKE RECEPTOR 3;

ANTIVIRAL ACTIVITY; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE RESPONSE; DISEASE ASSOCIATION; DISEASE EXACERBATION; HOST RESISTANCE; HUMAN; IMMUNE DYSREGULATION; INFECTION SENSITIVITY; INNATE IMMUNITY; INTERFERON PRODUCTION; INTRACELLULAR SIGNALING; MICROBIAL COLONIZATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SMOKING; VIRAL RESPIRATORY TRACT INFECTION; VIRUS VIRULENCE;

EID: 84871956015     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-0930     Document Type: Article

References (90)

1. US Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health; 2010.
2. World Health Organization. Mpower: a Policy Package to Reverse the Tobacco Epidemic. Geneva, Switzerland: World Health Organization; 2008.
3. Alwan A. Progress continues - nearly 3.8 billion people are now covered by an effective tobacco control measure. In: WHO Report on the Global Tobacco Epidemic. Geneva, Switzerland: World Health Organization; 2011:7.
4. Global Initiative for Chronic Obstructive Lung Disease. Management and prevention of COPD, 2011. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd.org/. Accessed December 14, 2011.
5. Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the economic burden of COPD in the US: a review and synthesis of the literature. COPD. 2006;3(4):211-218. (Pubitemid 44949061)
6. Benowitz NL. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med. 1988;319(20):1318-1330. (Pubitemid 19003394)
7. Centers for Disease Control and Prevention (CDC). Vital signs: current cigarette smoking among adults aged ≥ 18 years - United States, 2005-2010. MMWR Morb Mortal Wkly Rep. 2011;60(35):1207-1212.
8. Kalsheker N, Chappell S. The new genetics and chronic obstructive pulmonary disease. COPD. 2008;5(4):257-264.
9. Laumbach RJ, Kipen HM. Respiratory health effects of air pollution: update on biomass smoke and traffic pollution. J Allergy Clin Immunol. 2012;129(1):3-11.
10. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374(9691):733-743.
11. Górska K, Maskey-Warzechowska M, Krenke R. Airway inflammation in chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2010;16(2):89-96.
12. Wedzicha JA. Airway infection accelerates decline of lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(10 pt 1):1757-1758. (Pubitemid 33152304)
13. Tan WC, Xiang X, Qiu D, Ng TP, Lam SF, Hegele RG. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. Am J Med. 2003;115(4):272-277. (Pubitemid 37088188)
14. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114-1121. (Pubitemid 43726892)
15. Fuhrman C, Roche N, Vergnenègre A, Zureik M, Chouaid C, Delmas MC. Hospital admissions related to acute exacerbations of chronic obstructive pulmonary disease in France, 1998-2007. Respir Med. 2011;105(4):595-601.
16. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355-2365.
17. Kanner RE, Anthonisen NR, Connett JE; Lung Health Study Research Group. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001;164(3):358-364. (Pubitemid 32778199)
18. Gangl K, Reininger R, Bernhard D, et al. Cigarette smoke facilitates allergen penetration across respiratory epithelium. Allergy. 2009;64(3):398-405.
19. Burns AR, Hosford SP, Dunn LA, Walker DC, Hogg JC. Respiratory epithelial permeability after cigarette smoke exposure in guinea pigs. J Appl Physiol. 1989;66(5):2109-2116. (Pubitemid 19142358)
20. Foster WM. Mucociliary transport and cough in humans. Pulm Pharmacol Ther. 2002;15(3):277-282.
21. Laws TR, Davey MS, Titball RW, Lukaszewski R. Neutrophils are important in early control of lung infection by Yersinia pestis. Microbes Infect. 2010;12(4):331-335.
22. Tate MD, Deng YM, Jones JE, Anderson GP, Brooks AG, Reading PC. Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J Immunol. 2009;183(11):7441-7450.
23. Brown V, Elborn JS, Bradley J, Ennis M. Dysregulated apoptosis and NFkappaB expression in COPD subjects. Respir Res. 2009;10:24.
24. Fels AO, Cohn ZA. The alveolar macrophage. J Appl Physiol. 1986;60(2):353-369.
25. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med. 1995;152(5 pt 1):1666-1672. (Pubitemid 3002087)
26. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 1998;158(4):1277-1285. (Pubitemid 28489033)
27. Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2002;26(5):602-609. (Pubitemid 34315869)
28. Janeway CAJ, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease, 5th ed. New York, NY: Garland Publishing, 2001.
29. Hodge S, Hodge G, Scicchitano R, Reynolds PN, Holmes M. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol. 2003;81(4):289-296. (Pubitemid 36904336)
30. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med. 1997;155(3):852-857. (Pubitemid 27133393)
31. Saetta M, Baraldo S, Corbino L, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(2):711-717. (Pubitemid 29380694)
32. Tzortzaki EG, Siafakas NM. A hypothesis for the initiation of COPD. Eur Respir J. 2009;34(2):310-315.
33. Tamura S, Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis. 2004;57(6):236-247. (Pubitemid 40260238)
34. Reynolds HY. Modulating airway defenses against microbes. Curr Opin Pulm Med. 2002;8(3):154-165. (Pubitemid 34408994)
35. Holt PG, Strickland DH, Wikström ME, Jahnsen FL. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol. 2008;8(2):142-152. (Pubitemid 351161302)
36. Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol. 2009;9(5):377-384.
37. Taylor JD. COPD and the response of the lung to tobacco smoke exposure. Pulm Pharmacol Ther. 2010;23(5):376-383.
38. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378(9795):1015-1026.
39. Broz P, Monack DM. Molecular mechanisms of inflammasome activation during microbial infections. Immunol Rev. 2011;243(1):174-190.
40. Barber GN. Cytoplasmic DNA innate immune pathways. Immunol Rev. 2011;243(1):99-108.
41. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388(6640):394-397. (Pubitemid 27334820)
42. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17(1):1-14.
43. Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004;5(7):730-737. (Pubitemid 39023305)
44. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 1998;17(4):1087-1095. (Pubitemid 28077662)
45. Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM, Maniatis T. Virus infection induces the assembly of coordinately activated transcription factors on the IFN-β enhancer in vivo. Mol Cell. 1998;1(4):507-518. (Pubitemid 128374687)
46. Sonnenfeld G, Hudgens RW. Effect of sidestream and mainstream smoke exposure on in vitro interferon-alpha/beta production by L-929 cells. Cancer Res. 1986;46(6):2779-2783. (Pubitemid 16074281)
47. Bauer CM, Dewitte-Orr SJ, Hornby KR, et al. Cigarette smoke suppresses type I interferon-mediated antiviral immunity in lung fibroblast and epithelial cells. J Interferon Cytokine Res. 2008;28(3):167-179. (Pubitemid 351380149)
48. HuangFu WC, Liu J, Harty RN, Fuchs SY. Cigarette smoking products suppress anti-viral effects of type I interferon via phosphorylation-dependent downregulation of its receptor. FEBS Lett. 2008;582(21-22):3206-3210.
49. Rahman I, MacNee W. Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease. Am J Physiol. 1999;277(6 pt 1):L1067-L1088. (Pubitemid 30046033)
50. Gualano RC, Hansen MJ, Vlahos R, et al. Cigarette smoke worsens lung inflammation and impairs resolution of influenza infection in mice. Respir Res. 2008;9:53.
51. Bauer CM, Zavitz CC, Botelho FM, et al. Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS One. 2010;5(10):e13251.
52. Robbins CS, Bauer CM, Vujicic N, et al. Cigarette smoke impacts immune inflammatory responses to influenza in mice. Am J Respir Crit Care Med. 2006;174(12):1342-1351. (Pubitemid 44913036)
53. Kang MJ, Lee CG, Lee JY, et al. Cigarette smoke selectively enhances viral PAMP- and virus-induced pulmonary innate immune and remodeling responses in mice. J Clin Invest. 2008;118(8):2771-2784.
54. Mallia P, Message SD, Gielen V, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med. 2011;183(6):734-742.
55. Jaspers I, Horvath KM, Zhang W, Brighton LE, Carson JL, Noah TL. Reduced expression of IRF7 in nasal epithelial cells from smokers after infection with influenza. Am J Respir Cell Mol Biol. 2010;43(3):368-375.
56. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114-120. (Pubitemid 30245950)
57. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(2):349-355. (Pubitemid 32158511)
58. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(1):71-78. (Pubitemid 43069790)
59. Drannik AG, Pouladi MA, Robbins CS, Goncharova SI, Kianpour S, Stämpfli MR. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2004;170(11):1164-1171. (Pubitemid 39577373)
60. Botelho FM, Bauer CM, Finch D, et al. IL-1alpha/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice. PLoS One. 2011;6(12):e28457.
61. Gaschler GJ, Skrtic M, Zavitz CC, et al. Bacteria challenge in smoke-exposed mice exacerbates inflammation and skews the inflammatory profile. Am J Respir Crit Care Med. 2009;179(8):666-675.
62. Harvey CJ, Thimmulappa RK, Sethi S, et al. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci Transl Med. 2011;3(78):78ra32.
63. Phipps JC, Aronoff DM, Curtis JL, Goel D, O'Brien E, Mancuso P. Cigarette smoke exposure impairs pulmonary bacterial clearance and alveolar macrophage complement-mediated phagocytosis of Streptococcus pneumoniae. Infect Immun. 2010;78(3):1214-1220.
64. Bartlett NW, Walton RP, Edwards MR, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med. 2008;14(2):199-204. (Pubitemid 351214556)
65. Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2009;41(6):631-638.
66. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153(2):530-534.
67. Kuschner WG, D'Alessandro A, Wong H, Blanc PD. Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J. 1996;9(10):1989-1994. (Pubitemid 26333532)
68. Sapey E, Ahmad A, Bayley D, et al. Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol. 2009;29(4):508-516.
69. Bucchioni E, Kharitonov SA, Allegra L, Barnes PJ. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med. 2003;97(12):1299-1302. (Pubitemid 37526998)
70. Imaoka H, Hoshino T, Takei S, et al. Interleukin-18 production and pulmonary function in COPD. Eur Respir J. 2008;31(2):287-297.
71. Rovina N, Dima E, Gerassimou C, Kollintza A, Gratziou C, Roussos C. Interleukin-18 in induced sputum: association with lung function in chronic obstructive pulmonary disease. Respir Med. 2009;103(7):1056-1062.
72. de Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol. 2000;190(5):619-626. (Pubitemid 30164493)
73. Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax. 2002;57(7):590-595. (Pubitemid 34761760)
74. Botelho FM, Gaschler GJ, Kianpour S, et al. Innate immune processes are sufficient for driving cigarette smoke-induced inflammation in mice. Am J Respir Cell Mol Biol. 2010;42(4):394-403.
75. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095-2147. (Pubitemid 26086851)
76. Castro P, Legora-Machado A, Cardilo-Reis L, et al. Inhibition of interleukin-1beta reduces mouse lung inflammation induced by exposure to cigarette smoke. Eur J Pharmacol. 2004;498(1-3):279-286. (Pubitemid 39208090)
77. Doz E, Noulin N, Boichot E, et al. Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J Immunol. 2008;180(2):1169-1178.
78. Kang MJ, Homer RJ, Gallo A, et al. IL-18 is induced and IL-18 receptor alpha plays a critical role in the pathogenesis of cigarette smoke-induced pulmonary emphysema and inflammation. J Immunol. 2007;178(3):1948-1959. (Pubitemid 46154668)
79. Churg A, Zhou S, Wang X, Wang R, Wright JL. The role of interleukin-1beta in murine cigarette smoke-induced emphysema and small airway remodeling. Am J Respir Cell Mol Biol. 2009;40(4):482-490.
80. Hoshino T, Kato S, Oka N, et al. Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med. 2007;176(1):49-62. (Pubitemid 47048054)
81. Herfs M, Hubert P, Poirrier AL, et al. Proinflammatory cytokines induce bronchial hyperplasia and squamous metaplasia in smokers: implications for chronic obstructive pulmonary disease therapy. Am J Respir Cell Mol Biol. 2012;47(1):67-79.
82. Pauwels NS, Bracke KR, Dupont LL, et al. Role of IL-1α and the Nlrp3/caspase-1/IL-1β axis in cigarette smoke-induced pulmonary inflammation and COPD. Eur Respir J. 2011;38(5):1019-1028.
83. Kono H, Karmarkar D, Iwakura Y, Rock KL. Identification of the cellular sensor that stimulates the inflammatory response to sterile cell death. J Immunol. 2010;184(8):4470-4478.
84. Gaschler GJ, Zavitz CC, Bauer CM, et al. Cigarette smoke exposure attenuates cytokine production by mouse alveolar macrophages. Am J Respir Cell Mol Biol. 2008;38(2):218-226. (Pubitemid 351162844)
85. Eltom S, Stevenson CS, Rastrick J, et al. P2X7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke. PLoS One. 2011;6(9):e24097.
86. Lucattelli M, Cicko S, Müller T, et al. P2X7 receptor signaling in the pathogenesis of smoke-induced lung inflammation and emphysema. Am J Respir Cell Mol Biol. 2011;44(3):423-429.
87. Lommatzsch M, Cicko S, Müller T, et al. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(9):928-934.
88. Ferhani N, Letuve S, Kozhich A, et al. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(9):917-927.
89. Aronson MD, Weiss ST, Ben RL, Komaroff AL. Association between cigarette smoking and acute respiratory tract illness in young adults. JAMA. 1982;248(2):181-183. (Pubitemid 12078153)
90. Lee LY, Gu Q, Lin YS. Effect of smoking on cough reflex sensitivity: basic and preclinical studies. Lung. 2010;188(suppl 1):S23-S27.